GT201100321A - "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico" - Google Patents

"acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"

Info

Publication number
GT201100321A
GT201100321A GT201100321A GT201100321A GT201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A
Authority
GT
Guatemala
Prior art keywords
methyl
trifluorometil
benzazepin
tetrazol
trans
Prior art date
Application number
GT201100321A
Other languages
English (en)
Spanish (es)
Inventor
Scott Alan Frank
Xinchao Chen
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201100321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201100321A publication Critical patent/GT201100321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT201100321A 2009-06-30 2011-12-13 "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico" GT201100321A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
GT201100321A true GT201100321A (es) 2012-11-15

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201100321A GT201100321A (es) 2009-06-30 2011-12-13 "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"

Country Status (37)

Country Link
US (2) US8329688B2 (https=)
EP (1) EP2448933B1 (https=)
JP (1) JP5689875B2 (https=)
KR (1) KR101404893B1 (https=)
CN (1) CN102639528B (https=)
AR (1) AR077208A1 (https=)
AU (1) AU2010266537B2 (https=)
BR (1) BRPI1011931A2 (https=)
CA (1) CA2764425C (https=)
CL (1) CL2011003263A1 (https=)
CO (1) CO6480934A2 (https=)
CR (1) CR20110669A (https=)
DK (1) DK2448933T3 (https=)
DO (1) DOP2011000405A (https=)
EA (1) EA020600B1 (https=)
EC (1) ECSP11011551A (https=)
ES (1) ES2435293T3 (https=)
GT (1) GT201100321A (https=)
HR (1) HRP20130950T1 (https=)
IL (1) IL216655A (https=)
JO (1) JO2867B1 (https=)
MA (1) MA33385B1 (https=)
ME (1) ME01606B (https=)
MX (1) MX2011014024A (https=)
MY (1) MY157121A (https=)
NZ (1) NZ596820A (https=)
PE (1) PE20120538A1 (https=)
PL (1) PL2448933T3 (https=)
PT (1) PT2448933E (https=)
RS (1) RS52988B (https=)
SG (1) SG177413A1 (https=)
SI (1) SI2448933T1 (https=)
TN (1) TN2011000638A1 (https=)
TW (1) TWI450896B (https=)
UA (1) UA109409C2 (https=)
WO (1) WO2011002696A1 (https=)
ZA (1) ZA201108707B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
WO2014119947A1 (en) 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (https=) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
ATE316957T1 (de) 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Also Published As

Publication number Publication date
MX2011014024A (es) 2012-04-20
IL216655A0 (en) 2012-02-29
CN102639528B (zh) 2014-07-16
DK2448933T3 (da) 2013-10-07
WO2011002696A1 (en) 2011-01-06
JP2012532106A (ja) 2012-12-13
EA201270099A1 (ru) 2012-05-30
DOP2011000405A (es) 2012-01-15
IL216655A (en) 2015-02-26
SG177413A1 (en) 2012-02-28
SI2448933T1 (sl) 2013-11-29
TW201113275A (en) 2011-04-16
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
EP2448933A1 (en) 2012-05-09
US20100331309A1 (en) 2010-12-30
ES2435293T3 (es) 2013-12-18
UA109409C2 (ru) 2015-08-25
ZA201108707B (en) 2013-05-29
CO6480934A2 (es) 2012-07-16
US8329688B2 (en) 2012-12-11
US8299060B2 (en) 2012-10-30
KR101404893B1 (ko) 2014-06-20
AU2010266537B2 (en) 2013-04-18
CA2764425A1 (en) 2011-01-06
NZ596820A (en) 2013-07-26
CA2764425C (en) 2015-01-06
EP2448933B1 (en) 2013-08-28
JO2867B1 (en) 2015-03-15
EA020600B1 (ru) 2014-12-30
PT2448933E (pt) 2013-10-29
ECSP11011551A (es) 2012-01-31
HRP20130950T1 (hr) 2013-11-22
KR20120027426A (ko) 2012-03-21
CL2011003263A1 (es) 2012-07-27
MA33385B1 (fr) 2012-06-01
AR077208A1 (es) 2011-08-10
PE20120538A1 (es) 2012-05-09
AU2010266537A1 (en) 2012-02-02
TWI450896B (zh) 2014-09-01
TN2011000638A1 (en) 2013-05-24
MY157121A (en) 2016-05-13
BRPI1011931A2 (pt) 2016-04-19
PL2448933T3 (pl) 2014-01-31
US20120058990A1 (en) 2012-03-08
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
CR20110669A (es) 2012-03-16

Similar Documents

Publication Publication Date Title
GT201100321A (es) "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"
BRPI0906323A2 (pt) "artigo absorvente descartável do vestuário"
EP2506817A4 (en) Disposable wearing article
BR112012015790A2 (pt) 'artigo do vestuário'
IN2012DN00692A (https=)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
BR112012020349A2 (pt) "artigo do vestúario descartavel"
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
GEP20156216B (en) Heterocyclic compound and usage thereof
EP2482760A4 (en) OBJECT PURSUIT FOR ARTIFICIAL SEEING
BRPI0820515A2 (pt) "artigo do vestuário"
FR2933617B1 (fr) Compositions visant a favoriser le developpement et la croissance d'une microflore vaginale benefique
BRPI0916170A2 (pt) "artigo absorvente com característica de alívio de cintura"
BR112012016492A2 (pt) "artigo do vestuário descartavel"
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
BRPI1008858A2 (pt) "uso de análogos de ácido heteroaromáticos contendo enxofre como bactericidas"
IT1404145B1 (it) Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi
IT1395539B1 (it) Piede d'appoggio
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
EP2289147A4 (en) CONTROLLING THE BALANCE OF A BATTERY
HU0700024D0 (en) Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
EP2688957A4 (en) POLYMERIC COMPOSITIONS BASED ON BIOLOGICAL BASIS
EP2271365A4 (en) REGULATION OF FATTY ACID TRANSPORTERS
NZ596158A (en) Thioxanthene derivatives for the treatment of infectious diseases